乗り物酔い治療市場：医薬品タイプ別、治療タイプ別、剤形別、流通チャネル別、エンドユーザー別 - 2025年～2030年の世界予測

乗り物酔い治療市場は、2024年には7億1,969万米ドルとなり、2025年には7億4,093万米ドル、CAGR 3.07%で成長し、2030年には8億6,305万米ドルに達すると予測されています。

乗り物酔いは長い間、世界中で何百万人もの人々に影響を及ぼしている難題であり、その治療パラダイムは大きく変化しています。本レポートでは、現在の治療アプローチと新たな動向に焦点を当てながら、進化する業界を詳細に考察しています。研究が進み、消費者の嗜好が変化するにつれ、症状を緩和するだけでなく、患者の全体的な幸福感を高めることに改めて焦点が当てられています。

本イントロダクションでは、革新的な治療法、先進的な製剤、ユニークな剤形が、いかに患者ケアを再定義しつつあるかを包括的に解説します。臨床の正確さと市場の洞察のバランスを取りながら、この後のコンテンツでは、業界の変革、分析的なセグメンテーションの洞察、地域別の市場力学、主要な企業戦略について掘り下げています。各セグメントは、業界リーダーや意思決定者に、この競合情勢を乗り切るための明確で実行可能なロードマップを提供するために綿密に調査されています。

この分析は、厳密なデータ収集、専門家へのインタビュー、現代の市場力学に基づくものであり、読者は現在の実践と将来の方向性の両方について全体的な概観を得ることができます。伝統的な治療オプションと最新のイノベーションの両方を取り上げることで、本レポートは利害関係者に対し、様々な治療法や流通チャネルにまたがる統合的アプローチを検討するよう促しています。そうすることで、臨床的有効性だけでなく、市場の実行可能性や患者の利便性も反映された叙述となることを保証しています。

乗り物酔い治療市場を形成する進化する動向

近年、乗り物酔い治療の状況は大きく変化しています。技術の進歩により、診断能力やウェアラブル・センシング・デバイスが強化されただけでなく、革新的なドラッグ・デリバリー・システムも登場しています。こうしたシフトにより、市場は従来の治療プロトコルから、よりオーダーメイドで効率的な、患者中心のアプローチへと移行しています。

最も注目すべき変化のひとつは、デジタルヘルス技術の統合が進んでいることです。デジタル治療とリアルタイムのモニタリングは、様々な治療オプションに対する患者の反応を評価する上で不可欠なものとなり、より個別化されたケア戦略を可能にしています。薬理学の革新は、吸収を改善し副作用を最小限に抑える改良型剤形の開発につながりました。このようなダイナミックな状況の中で、従来の治療法は、安全性と有効性が大幅に改善された現代的な治療法によって補完され、場合によっては取って代わられつつあります。

もう一つの変革的動向は、消費者行動の進化です。情報に敏感な患者は治療の選択肢を明確にすることを求めるようになり、企業は革新的で先進的な戦略を採用するようになりました。従来の市販薬や処方薬に加えて自然療法を取り入れる治療法へのシフトが顕著になっています。さらに、市場開拓戦略には、アプリやモニタリングツールを開発するためのハイテク企業との戦略的提携がますます含まれるようになり、アクセス可能な治療洞察や患者管理の実践の幅が広がっています。

この進化する状況は、科学的なブレークスルーと、統合されたヘルスケアソリューションの重要性を認識する市場視点の融合によって特徴付けられます。開業医も投資家も同様に持続可能な成長の道を模索する中、この分野では臨床研究と市場主導型イノベーションの強固な相互作用が示されています。製剤の改良から先進的なデリバリー・チャネルに至るまで、ホリスティックなアプローチを治療に取り入れようとする動きが、今日の市場の変革的性質を裏付けています。

現在進行中の議論の中心は、単に個々の治療法の有効性だけでなく、新たな技術や革新的なビジネスモデルが、乗り物酔い対策の将来をどのように規定するかということです。規制機関が新製品や治療プロトコルの認可を合理化する中、業界はかつてないレベルの協力、調査、市場浸透の態勢を整えています。

乗り物酔い治療における包括的なセグメンテーションの洞察

乗り物酔い治療市場を理解する上で重要な点は、その複雑なセグメンテーションです。業界を分析すると、市場調査は薬剤の種類に基づくセグメンテーションから始まり、かなり微妙なニュアンスで行われていることがわかる。この観点では、抗コリン薬と抗ヒスタミン薬を中心とした治療法を検討し、それぞれのクラスが症状を予防・緩和するための明確なメカニズムを提供していることを強調します。これらの化合物の微妙な薬力学は、臨床診療のガイドラインとしてだけでなく、将来の研究開発の指標としても役立ちます。

さらに、治療の種類というプリズムを通じたセグメンテーションも存在し、市場は自然療法、市販薬、処方薬に分けられます。このような差別化は、地域によって異なる患者のニーズや規制の状況を反映するものであり、極めて重要です。自然療法は安全性と副作用の少なさが評価され、人気を博しています。一方、処方薬はより重篤な症例に対応するため、効能と安全性のバランスの取れたアプローチが必要となります。

分析は、注射剤、経口剤、経皮パッチ剤に区分される剤形について検討を続ける。それぞれの剤形は、特定の患者層や臨床シナリオに関連しています。注射剤は急性症状に対応することが多く、経口剤は常用に便利です。経皮吸収型パッチは、徐放性メカニズムにより、安定した治療レベルを提供し、血漿中濃度の変動を最小限に抑えながら効果を最大化するドラッグデリバリーの現代的アプローチを具現化しています。

セグメンテーションのもう1つの層は、オンライン薬局と小売薬局に分かれた流通チャネルに焦点を当てています。このセグメンテーションは、消費者の購買行動の進化だけでなく、医薬品業界におけるデジタル変革の重要性の高まりも反映しています。デジタルプラットフォームへの信頼の高まりは、より幅広い患者層にリーチし、治療介入をタイムリーかつ効率的に提供することを可能にするeコマースの役割を浮き彫りにしています。

最後に、診療所、在宅医療、病院など、エンドユーザーに基づくセグメンテーションは、市場の多面的な性質を明確に示すものです。診療所は初期診断と治療のセンターとして機能することが多く、在宅ケアソリューションは慢性的な症状や重症度の低い症状に対して利便性を提供します。病院は、重要かつ緊急なケアの必要性を示すものであり、管理とモニタリングにより構造化されたアプローチを採用することが多いです。これらの差別化されたセグメントが提供する重層的な洞察は、戦略的プランニングと市場ポジショニングに不可欠な包括的フレームワークを構築します。

これらのセグメンテーション戦略を理解することは、市場戦略担当者だけでなく、医薬品イノベーターや臨床医にとっても不可欠です。各セグメントは相互に関連しながらも、市場全体のダイナミクスを形成するユニークな課題と機会を提供し、患者のニーズと臨床の進歩の両方に適応し、対応し続ける治療環境を保証します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 乗り物酔い症状を発症するリスクが高い高齢化人口の増加
    • さまざまな年齢層で運動誘発性不快感の有病率が上昇
    • 世界の旅行と観光の動向の高まりにより、効果的な乗り物酔い治療ソリューションの需要が高まっています。
  • 抑制要因
    • 開発および製造コストの高さが手頃な価格と収益性に影響
  • 機会
    • 交通・観光業界と連携し、乗り物酔いの予防ソリューションを提供
    • 遺伝子検査と生体認証検査による個別化医療アプローチの実施
  • 課題
    • 新たな治療法の有効性に対する消費者の懐疑心が、市場での急速な受け入れを妨げている
• 市場セグメンテーション分析
  • 薬剤の種類：抗コリン薬が総合的な乗り物酔い管理と患者中心のケア戦略に与える影響の増大
  • エンドユーザー：複雑な乗り物酔いの症例に対処する病院の役割が増大し、高度な医療技術が生まれました。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 乗り物酔い治療市場：治療タイプ別

• 抗コリン薬
• 抗ヒスタミン薬

第7章 乗り物酔い治療市場：治療タイプ別

• 自然療法
• 市販薬
• 処方薬

第8章 乗り物酔い治療市場：剤形別

• 注射
• 経口
• 経皮パッチ

第9章 乗り物酔い治療市場：流通チャネル別

• オンライン薬局
• 小売薬局

第10章 乗り物酔い治療市場：エンドユーザー別

• クリニック
• ホームケア
• 病院

第11章 南北アメリカの乗り物酔い治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の乗り物酔い治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの乗り物酔い治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amneal Pharmaceuticals LLC
• Astellas Pharma Inc.
• Baxter International Inc.,
• Bayer AG
• BONINE by Wellspring Pharmaceutical Corporation
• Cipla Limited
• CVS Health Corporation
• GlaxoSmithKline plc
• Lupin Limited
• Myungmoon Pharma Co. Ltd.
• Novartis AG
• Perrigo Company PLC
• Pfizer Inc.
• Prestige Consumer Healthcare Inc.,
• Reliefband Technologies LLC
• Sanofi S.A.
• Taj Pharmaceuticals Limited
• Teva Pharmaceutical Industries Limited
• Torrent Pharmaceuticals Ltd
• WellSpring Pharmaceutical Corporation

LIST OF FIGURES

• FIGURE 1. MOTION SICKNESS TREATMENT MARKET MULTI-CURRENCY
• FIGURE 2. MOTION SICKNESS TREATMENT MARKET MULTI-LANGUAGE
• FIGURE 3. MOTION SICKNESS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 4. MOTION SICKNESS TREATMENT MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. MOTION SICKNESS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. MOTION SICKNESS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. MOTION SICKNESS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MOTION SICKNESS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY NATURAL REMEDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 42. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 74. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 160. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 180. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 185. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 234. MOTION SICKNESS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 235. MOTION SICKNESS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

The Motion Sickness Treatment Market was valued at USD 719.69 million in 2024 and is projected to grow to USD 740.93 million in 2025, with a CAGR of 3.07%, reaching USD 863.05 million by 2030.

Motion sickness has long been a challenging condition affecting millions globally, and its treatment paradigm is undergoing significant change. The present report offers an in-depth look at the evolving industry, highlighting current therapeutic approaches and emerging trends. As research advances and consumer preferences shift, there is a renewed focus on not only alleviating symptoms but also enhancing overall patient well-being.

This introduction sets the stage for a comprehensive exploration of how innovative treatments, advanced drug formulations, and unique dosage forms are redefining patient care. With a balance of clinical precision and market insight, the content that follows delves into industry transformations, analytical segmentation insights, regional market dynamics, and key corporate strategies. Each segment is meticulously examined to provide industry leaders and decision-makers with a clear, actionable roadmap for navigating this competitive landscape.

This analysis is grounded in rigorous data collection, expert interviews, and contemporary market dynamics, ensuring that readers obtain a holistic overview of both current practices and future directions. By addressing both traditional treatment options and modern innovations, the report encourages stakeholders to consider integrative approaches that span various therapies and distribution channels. In doing so, it ensures that the narrative reflects not just clinical efficacy but also market viability and patient convenience.

Evolving Trends Shaping the Motion Sickness Treatment Market

In recent years, the treatment landscape for motion sickness has experienced transformative shifts. Technological advancements have not only enhanced diagnostic capabilities and wearable sensing devices but have also led to innovative drug delivery systems. These shifts have moved the market away from conventional treatment protocols towards approaches that are more tailored, efficient, and patient-centric.

One of the most notable changes is the increasing integration of digital health technology. Digital therapeutics and real-time monitoring have become integral in assessing patient response to various treatment options, enabling more personalized care strategies. Innovations in pharmacology have resulted in the development of enhanced dosage forms that improve absorption and minimize side effects. In this dynamic climate, conventional interventions are being supplemented-and in some cases replaced-by contemporary therapies that offer significant improvements in safety and efficacy.

Another transformative trend is the evolution in consumer behavior. Informed patients now demand clarity on treatment options, driving companies to innovate and adopt forward-thinking strategies. There is a notable shift towards therapies that embrace natural remedies alongside traditional over-the-counter and prescription medications. Furthermore, market strategies increasingly include strategic partnerships with tech firms to develop apps and monitoring tools, broadening the scope of accessible treatment insights and patient management practices.

This evolving landscape is characterized by a blend of scientific breakthroughs and a market perspective that recognizes the importance of integrated healthcare solutions. As practitioners and investors alike look for sustainable growth avenues, the sector is witnessing a robust interplay between clinical research and market-driven innovation. The drive to incorporate holistic approaches in treatment-encompassing everything from improved drug formulations to advanced delivery channels-underscores the transformative nature of the market today.

The ongoing discourse centers not merely on the efficacy of individual treatments but also on how emerging technologies and innovative business models can collectively define the future of motion sickness management. As regulatory bodies streamline the approval of new products and treatment protocols, the industry finds itself poised for unprecedented levels of collaboration, research, and market penetration.

Comprehensive Segmentation Insights in Motion Sickness Treatment

A critical aspect of understanding the motion sickness treatment market is its complex segmentation. Analysis of the industry reveals that market studies are conducted with considerable nuance, beginning with segmentation based on the type of drugs. This perspective examines treatments centered on anticholinergics and antihistamines, highlighting how each class offers distinct mechanisms for preventing and alleviating symptoms. The nuanced pharmacodynamics of these compounds serve not only as a guideline for clinical practice but also as a marker for future research developments.

Further segmentation exists through the prism of treatment type, where the market is divided among natural remedies, over-the-counter medications, and prescription medications. Such differentiation is crucial as it reflects varied patient needs and regulatory conditions across regions. Natural remedies have gained traction due to perceived safety and minimal side effects, whereas over-the-counter medications underscore accessibility and ease of use. Prescription medications, on the other hand, cater to more severe cases, requiring a balanced approach between potency and safety considerations.

The analysis continues by examining the dosage forms, which are segmented into injectable, oral, and transdermal patches. Each dosage form is associated with specific patient demographics and clinical scenarios. Injectable formulations often cater to acute episodes, while oral medications offer convenience for regular use. Transdermal patches, through sustained release mechanisms, offer the advantage of steady therapeutic levels, embodying a modern approach to drug delivery that maximizes efficacy while minimizing fluctuations in plasma concentration.

Another layer of segmentation focuses on the distribution channel, divided between online pharmacies and retail pharmacies. This segmentation not only reflects evolving consumer buying behaviors but also the growing importance of digital transformation in the pharmaceutical industry. The increasing trust in digital platforms underscores the role of e-commerce in reaching a broader patient base, enabling timely and efficient delivery of therapeutic interventions.

Lastly, segmentation based on the end user-including clinics, home care scenarios, and hospitals-provides a clear picture of the market's multi-dimensional nature. Clinics often serve as centers for initial diagnosis and treatment, while home care solutions offer convenience for chronic or less severe conditions. Hospitals, exemplifying the need for critical and immediate care, often adopt a more structured approach to administration and monitoring. The layered insights offered by these differentiated segments create a comprehensive framework that is critical for strategic planning and market positioning.

Understanding these segmentation strategies is essential not only for market strategists but also for pharmaceutical innovators and clinicians. Each segment, though interconnected, provides unique challenges and opportunities that shape the overall market dynamics, ensuring that the treatment landscape remains adaptable and responsive to both patient needs and clinical advancements.

Based on Type Of Drugs, market is studied across Anticholinergics and Antihistamines.

Based on Treatment Type, market is studied across Natural Remedies, Over-the-Counter Medications, and Prescription Medications.

Based on Dosage Forms, market is studied across Injectable, Oral, and Transdermal Patches.

Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies.

Based on End User, market is studied across Clinics, Home Care, and Hospitals.

Regional Overview of Global Motion Sickness Treatment Markets

The regional dynamics of the motion sickness treatment market underscore significant variability and growth potential. Market insights indicate that the Americas, a region rich in advanced healthcare infrastructure, continue to be a leader in adopting new treatments and technologies. Here, rising awareness and a strong network of healthcare providers combine with an active pharmaceutical market, driving innovation and investment in both traditional and novel treatment methods.

In contrast, the Europe, Middle East & Africa region presents a unique mix of opportunities and challenges driven by differing regulatory landscapes and varying levels of technological adoption. Regulatory frameworks in Europe promote rigorous clinical testing and approval processes, ensuring that technological innovations meet high safety standards. Meanwhile, regions within the Middle East and Africa are witnessing increased investment in healthcare infrastructure, fostering an environment ripe for adopting advanced therapeutic approaches. Such variation necessitates adaptable strategies that cater to local market dynamics while aligning with global best practices.

The Asia-Pacific region, with its robust manufacturing capabilities and rapidly growing consumer base, is emerging as a critical market for motion sickness treatment. The region's dynamic growth is backed by a combination of traditional medical practices and modern pharmaceutical advancements. This dual approach is particularly beneficial in addressing both acute and chronic conditions of motion sickness, thereby contributing to a balanced market portfolio that spans from innovative drug formulations to traditional over-the-counter solutions.

Cross-regional analysis reveals that while each region faces its unique set of challenges-ranging from regulatory hurdles to cultural preferences-the overarching trends indicate an increasing harmonization of treatment protocols and market practices. Global connectivity has paved the way for shared innovations, with pharmaceutical research increasingly drawing on insights from diverse geographical areas. Such a synthesis of regional strengths not only enhances the overall quality of motion sickness treatment but also fosters an environment of collaboration between emerging and established markets.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Corporate Key Players Shaping the Motion Sickness Treatment Market

A review of key companies reveals a competitive environment where major players are driving change through innovation, strategic partnerships, and robust market positioning. Amneal Pharmaceuticals LLC and Astellas Pharma Inc. are renowned for their commitment to research and for offering effective anticholinergic and antihistaminic formulations that align with the unique needs of their patient bases. Baxter International Inc. and Bayer AG, with their extensive portfolio of over-the-counter products, have remained at the forefront of delivering accessible solutions that are widely trusted by consumers.

BONINE by Wellspring Pharmaceutical Corporation and Cipla Limited have further expanded the market by investing in advanced dosage forms and adopting rigorous quality control measures. CVS Health Corporation and GlaxoSmithKline plc have emerged as leaders in integrating digital health solutions into their distribution channels, thereby providing a seamless purchase experience for patients. Companies such as Lupin Limited and Myungmoon Pharma Co. Ltd. are recognized for their innovative approaches to prescription medications, offering alternatives that combine traditional pharmaceutical excellence with modern therapeutic benefits.

Novartis AG and Perrigo Company PLC are known for their targeted investments in research and development, focusing on the creation of new dosage forms like transdermal patches and sophisticated oral formulations that enhance patient compliance. Pfizer Inc. and Prestige Consumer Healthcare Inc. continue to leverage their global networks to drive market penetration, securing significant market shares through strategic collaborations. Reliefband Technologies LLC has carved a niche by introducing wearable solutions that complement pharmacological interventions, while Sanofi S.A. champions next-generation therapies that address the entire spectrum of motion sickness.

Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Ltd, and WellSpring Pharmaceutical Corporation round out the list of key companies, each contributing uniquely to the dynamic market environment. Their combined efforts in research, innovation, and market expansion have fostered an ecosystem that nurtures continuous growth and resilience. These companies' commitment to clinical excellence and market adaptability underscores a broader industry trend focused on leveraging innovation to meet fluctuating consumer demands and stringent regulatory requirements.

Together, these industry leaders form a mosaic of expertise that spans global regions and a wide range of therapeutic needs. Their concerted efforts not only underscore the competitive spirit of the market but also highlight the collaborative potential that drives continuous improvement in motion sickness treatment.

The report delves into recent significant developments in the Motion Sickness Treatment Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals LLC, Astellas Pharma Inc., Baxter International Inc.,, Bayer AG, BONINE by Wellspring Pharmaceutical Corporation, Cipla Limited, CVS Health Corporation, GlaxoSmithKline plc, Lupin Limited, Myungmoon Pharma Co. Ltd., Novartis AG, Perrigo Company PLC, Pfizer Inc., Prestige Consumer Healthcare Inc.,, Reliefband Technologies LLC, Sanofi S.A., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Ltd, and WellSpring Pharmaceutical Corporation. Strategic Recommendations for Advancing Motion Sickness Treatment Innovation

Industry leaders are encouraged to adopt a multi-faceted strategy to maintain competitive advantage and pioneer future innovations in motion sickness treatment. First, it is imperative to invest heavily in research and development to identify new therapeutic compounds that offer increased efficacy with reduced side effects. Strengthening R&D will catalyze the discovery of novel drug delivery systems-particularly in improving the bioavailability of both natural and synthetic remedies-thus ensuring treatments remain at the cutting edge of medical science.

Leveraging digital transformation is another key action point. Implementing advanced digital monitoring tools and integrating telemedicine solutions can greatly enhance patient management. Such digital strategies not only facilitate real-time data collection but also enable personalized treatment approaches that adjust to individual patient needs. As a result, companies can optimize therapy outcomes while ensuring a seamless patient experience.

Furthermore, fostering robust partnerships is essential. Collaborative efforts with technology companies, regulatory bodies, and academic institutions can unlock new insights that drive product innovation and market expansion. Strategic alliances can expedite the clinical trial processes and streamline regulatory approvals, offering companies a competitive edge in bringing next-generation therapies to market.

The importance of diversifying product portfolios cannot be overstated. Expanding offerings to include a range of dosage forms-such as injectables, oral medications, and transdermal patches-appears critical in catering to various clinical profiles and patient preferences. With an eye on market segmentation insights, companies should adapt their products to fit diverse distribution channels, whether via digital commerce or traditional retail pharmacies, enhancing overall market penetration.

Additionally, focusing on geographic diversification is recommended. Tailoring strategies to meet the unique regulatory and cultural needs of key regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific will help in maximizing market share. This might include localized clinical studies, region-specific marketing campaigns, and adaptations of product formulations to meet local consumer demands.

Lastly, industry leaders should continually monitor emerging trends and regulatory shifts. Staying abreast with global best practices and anticipating market disruptions through proactive policy alignment can provide significant strategic benefits. In an industry that is characterized by rapid innovation and stringent compliance requirements, a forward-thinking approach that marries clinical excellence with technological integration and strategic market positioning will prove indispensable.

Conclusion: Future Trajectories in Motion Sickness Treatment

Through rigorous analysis and detailed market segmentation, it becomes evident that the motion sickness treatment market is on the cusp of substantial evolution. The convergence of advanced pharmaceutical research, digital transformation, and strategic industry collaborations has created an environment ripe for innovative breakthroughs. Key insights reveal that from drug type classifications and treatment modality considerations to nuanced segmentation based on dosage forms, distribution channels, and end users, every facet of the market is interlinked with both clinical efficiency and market dynamics.

As treatment strategies are refined and tailored to specific patient needs, it is clear that future progress depends on a balanced approach that integrates both legacy therapies and modern innovations. The regional disparities and opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific underscore the importance of a global perspective in developing comprehensive treatment protocols. Moreover, major industry players continue to push the envelope through rigorous R&D, strategic partnerships, and adaptive market strategies that cater to ever-evolving consumer demands.

This convergence of clinical rigor and market responsiveness is not only setting new benchmarks for treatment efficacy but is also reshaping the broader healthcare landscape. The continuous collaboration between researchers, healthcare providers, and industry leaders is essential for driving forward a new era of motion sickness management, one that is rooted in both scientific integrity and commercial dynamism. In essence, the motion sickness treatment landscape of tomorrow promises to be more integrated, patient-centric, and innovation-driven than ever before.

The insights summarized herein serve as a call for sustained investment, strategic foresight, and collaborative synergy, underscoring the need for stakeholders to not only respond to current trends but also anticipate future challenges. The future trajectory of this market, buoyed by technological and pharmaceutical innovations, signals robust growth and enhanced patient outcomes, marking an exciting era for all industry participants.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing aging population with a higher risk of developing motion sickness symptoms
    • 5.1.1.2. Rising prevalence of motion-induced discomfort among diverse age groups
    • 5.1.1.3. Growing global travel and tourism trends led to demand for effective motion sickness treatment solutions
  • 5.1.2. Restraints
    • 5.1.2.1. High development and manufacturing costs impacting affordability and profitability
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborating with transportation and tourism sectors to provide preventative motion sickness solutions
    • 5.1.3.2. Implementing personalized medicine approaches through genetic and biometric testing
  • 5.1.4. Challenges
    • 5.1.4.1. Consumer skepticism regarding the efficacy of emerging treatments hampers rapid market acceptance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type Of Drugs: Rising impact of anticholinergics on comprehensive motion sickness management and patient-centric care strategies

• 5.2.2. End User: Increasing role of hospitals in addressing complex motion sickness cases led to advanced medical technologies

• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Motion Sickness Treatment Market, by Type Of Drugs

• 6.1. Introduction
• 6.2. Anticholinergics
• 6.3. Antihistamines

7. Motion Sickness Treatment Market, by Treatment Type

• 7.1. Introduction
• 7.2. Natural Remedies
• 7.3. Over-the-Counter Medications
• 7.4. Prescription Medications

8. Motion Sickness Treatment Market, by Dosage Forms

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral
• 8.4. Transdermal Patches

9. Motion Sickness Treatment Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Online Pharmacies
• 9.3. Retail Pharmacies

10. Motion Sickness Treatment Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Home Care
• 10.4. Hospitals

11. Americas Motion Sickness Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Motion Sickness Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Motion Sickness Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Amazon transforms healthcare delivery by integrating virtual consultations with upfront pay-per-visit pricing
  • 14.3.2. Panav Biotech launches FDA-approved Maropitine Injection to enhance pet care
  • 14.3.3. Zydus Lifesciences secures USFDA approval for its scopolamine transdermal system to transform motion sickness treatment
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amneal Pharmaceuticals LLC
• 2. Astellas Pharma Inc.
• 3. Baxter International Inc.,
• 4. Bayer AG
• 5. BONINE by Wellspring Pharmaceutical Corporation
• 6. Cipla Limited
• 7. CVS Health Corporation
• 8. GlaxoSmithKline plc
• 9. Lupin Limited
• 10. Myungmoon Pharma Co. Ltd.
• 11. Novartis AG
• 12. Perrigo Company PLC
• 13. Pfizer Inc.
• 14. Prestige Consumer Healthcare Inc.,
• 15. Reliefband Technologies LLC
• 16. Sanofi S.A.
• 17. Taj Pharmaceuticals Limited
• 18. Teva Pharmaceutical Industries Limited
• 19. Torrent Pharmaceuticals Ltd
• 20. WellSpring Pharmaceutical Corporation